Understanding how drug delivery systems distribute in vivo remains a major challenge in developing nanomedicines. Especially ...

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal that combines two of the world's leaders in mRNA treatments.